Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin in active SLE
NCT02533570Phase 2Terminated
- Sponsor
- Seagen Inc.
- Start
- Jul 2015
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in systemic lupus erythematosus (SLE), sponsored by Seagen Inc.. Started Jul 2015; status: terminated.
02
Drugs
brentuximab vedotin
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02533570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02533570.